Business Context and Reporting Period
Company: Supernus Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: February 08, 2016
Event: Announcement of a favorable federal court ruling regarding patent infringement and validity for the Company's product Oxtellar XR.
Key Financial Metrics
This filing is a Current Report (Form 8-K) regarding a legal event and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Legal Developments
On February 08, 2016, following a seven-day bench trial, Judge Renee Marie Bumb of the United States District Court for the District of New Jersey issued a ruling in favor of Supernus Pharmaceuticals, Inc. against Actavis Inc. and its subsidiaries. Key aspects of the ruling include:
- Infringement: The court ruled that Actavis infringed U.S. Patent Nos. 7,722,898 and 7,910,131 by submitting an Abbreviated New Drug Application (ANDA) to the FDA for a generic version of Oxtellar XR prior to patent expiration.
- Validity: The court ruled that U.S. Patent Nos. 7,722,898, 7,910,131, and 8,617,600 are valid.
- Patent Expiration: The FDA's Orange Book lists the three patents subject to the decision as expiring on April 13, 2027.
- Additional Protection: Oxtellar XR is further protected by two other patents listed in the Orange Book with expiration dates no earlier than 2027.
- ANDA Status: As of the filing date, the Company was not aware of any FDA approval for the Actavis ANDA.
Guidance, Outlook, and Risks
The filing does not provide updated financial guidance or management commentary on future financial performance. The primary risk addressed is the threat of generic competition for Oxtellar XR, which was mitigated by the court's finding of infringement and patent validity. The Company notes that no FDA approval for the generic version was known at the time of the report.
Investor Verification Checklist
- Verify the current status of the Actavis ANDA with the FDA to confirm if approval has been granted since February 08, 2016.
- Confirm the expiration dates of the two additional patents protecting Oxtellar XR mentioned in the filing.
- Monitor for any appeals filed by Actavis Inc. regarding the District Court's ruling.
- Review subsequent quarterly reports (10-Q) or annual reports (10-K) for financial impact related to the continued exclusivity of Oxtellar XR.